Combined with our previously published results that showed higher sensitivity of epithelial cancer cells to MEK inhibitors (11), we investigated the combination of CDK4 and MEK inhibitors in multiple preclinical models that recapitulate EMT-mediated tumor heterogeneity and demonstrated this as an effective strategy to combat heterogeneity and resistance. The gene discussed is CDK4; the disease is neoplasm.